New Guidelines for CKD

CE / CME

Steering Through Change: Adapting to New Guidelines in CKD Evaluation and Management

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: February 26, 2025

Expiration: February 25, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this text-based module, Dr Mark J. Sarnak provides an overview of the Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), including screening, diagnosis, and treatment, as well as potential challenges to the implementation of guideline recommendations and how to overcome such barriers.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with CKD do you provide care for in a typical week?

According to the KDIGO 2024 guideline, what is the recommended approach for early screening and detection of CKD to support multidisciplinary collaboration and prevent cardiovascular and renal events?

A 65-year-old patient with CKD stage 3b, type 2 diabetes, and albuminuria (uACR 300 mg/g) is on a RAAS inhibitor. According to the 2024 KDIGO 2024 guideline, which additional therapy should be initiated to reduce kidney and cardiovascular risks?